Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide to Ameliorate Tuberous Sclerosis Complex Hyperexcitable Behaviors
2016-002408-13Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bumetanide in tuberous sclerosis complex (TSC) and Tuberous Sclerosis Complex Associated Neuropsychiatric Disorder (TAND), sponsored by University Medical Center Utrecht. Primary endpoint: ABC-I scale. Started Jul 2016; status: active.
02
Drugs
bumetanide
03
Conditions
tuberous sclerosis complex (TSC)Tuberous Sclerosis Complex Associated Neuropsychiatric Disorder (TAND)
Beyond the preview
Go deeper on 2016-002408-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002408-13.